Flow Cytometric Evaluation of Biomarkers

临床定量流式细胞术是一种新技术，其利用专门的抗体染色技术和荧光标准品来定量与样品中不同细胞群结合的抗体。流式细胞术单元使用该技术定量接受各种基于抗体的治疗的患者的肿瘤细胞抗体结合能力。使用放射性标记的抗体进行流式细胞术测定代替先前的研究。流式细胞术测定更快速，不需要使用放射性，并且在100 uL血液而不是25 mL血液上进行。收集的数据也更精确，并提高了NCI研究人员比较抗体与肿瘤细胞结合与治疗反应的能力。在治疗后立即定量荧光抗体结合还允许精确测定抗原位点与未标记的治疗性抗体的饱和度。由于大多数NCI淋巴瘤和白血病方案在其方案中包括基于抗体的治疗，这对NCI研究人员来说是一个巨大的资源。参考实验室未提供抗体结合定量。

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antibody binding to different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antibody binding capacity in patients undergoing various antibody based therapies. The flow cytometric assays are performed in place of previous studies using radioactively labeled antibodies. The flow cytometric assays are more rapid, make the use of radioactivity unnecessary and are performed on 100 uL of blood instead of 25mL. The data collected is also more precise and improves the ability of NCI investigators to compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. As the majority of NCI lymphoma and leukemia protocols include antibody based therapy in their regimens, this is a tremendous resource for NCI investigators. Antibody binding quantitation is not provided by reference laboratories.